Cardiff-by-the-Sea, CA, United States of America

Benjamin Jones

This inventor holds 28 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 12 EPO patents, primarily in Heterocyclic Compounds. Top assignees: Takeda Pharmaceutical Company Limited, Bayer Pharmaceuticals Corporation, Bayer Healthcare LLC. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Benjamin Jones. Retrieved from https://idiyas.com/inventor/benjamin-jones

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 10)

% Patents Active = 53.6

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 12 (Patent Applications = 16)

Average Co-Inventor Count = 7.3

ph-index = 6

Forward Citations = 118(Granted Patents)

Location History:

Hamden, CT (US) (2006 - 2011)
New Haven, CT (US) (2009 - 2012)
Turlock, CA (US) (2017)
Cardiff-by-the-Sea, CA (US) (2011 - 2019)
San Diego, CA (US) (2013 - 2023)

Company Filing History:

17 out of 1,226

Takeda Pharmaceutical Company Limited

patents

4 out of 71

Bayer Pharmaceuticals Corporation

Bellwether Coffee Co.

Years Active: 2006-2026

Loading Chart...

Areas of Expertise:

SSTR4 Agonists

PHD Inhibitors

GPR6 Modulators

Tricyclic Pyridones

Fused Heteroaromatic

Poly(ADP-Ribose) Polymerase

Renin Inhibitors

Hyper-Proliferative Disorders

Benzofuran Derivatives

Pyrrolotriazine Derivatives

Polo-Like Kinase Inhibitors

Angiogenesis

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12741957 - N-heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists (2026-09-22),

2. 12162893 - Tricyclic pyridones and pyrimidones (2024-12-10),

3. 11845761 - Tricyclic pyridones and pyrimidones (2023-12-19),

4. 11426397 - Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 (2022-08-30),

5. 10407409 - 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD (2019-09-10),

6. 10362798 - Roasting system with clean emissions and high thermal efficiency (2019-07-30),

7. 9944626 - 6-(5-hydroxy-1H-pyrazol-1-YL)nicotinamide inhibitors of PHD (2018-04-17),

8. 9708296 - 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD (2017-07-18),

9. 9669966 - Method and apparatus for wine bottle packaging and display (2017-06-06),

10. 9345713 - 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD (2016-05-24),

11. 9187497 - Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) (2015-11-17),

12. 9181255 - Fused heteroaromatic pyrrolidinones as SYK inhibitors (2015-11-10),

13. 9108970 - Fused heteroaromatic pyrrolidinones (2015-08-18),

14. 9040522 - 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD (2015-05-26),

15. 8822470 - Substituted pyrido[2,3-b]pyrazines (2014-09-02),

Title: Benjamin D Jones: A Pioneer in Pharmaceutical Innovations

Introduction:

Benjamin D Jones, a prolific inventor based in New Haven, CT, has made significant contributions to the field of pharmaceuticals with a total of 7 patents to his name. His groundbreaking work focuses on developing compounds for treating hyper-proliferative disorders and diseases associated with angiogenesis.

Latest Patents:

Jones' latest patents include pyrrolotriazine derivatives that show promise in the prevention and treatment of hyper-proliferative disorders linked to angiogenesis. Additionally, his 2-oxo-1,3,5-perhydrotriazapine derivatives offer potential solutions for hyper-proliferative, angiogenesis, and inflammatory disorders.

Career Highlights:

Having worked at Bayer Pharmaceuticals Corporation and Bayer Healthcare LLC, Jones has honed his expertise in developing novel pharmaceutical compounds. His innovative approach to drug discovery has garnered recognition within the industry for its potential to revolutionize treatment methods.

Collaborations:

Throughout his career, Jones has collaborated with esteemed colleagues such as Barton W Phillips and Jacques P Dumas. These partnerships have fostered creativity and knowledge exchange, leading to the successful development of cutting-edge pharmaceutical solutions.

Conclusion:

Benjamin D Jones stands as a pioneering figure in the realm of pharmaceutical innovations, with a commendable track record of patents that address critical medical needs. His collaborations and career milestones underscore his dedication to advancing healthcare through inventive solutions.

Profile summary based on public USPTO records.